Top ▲

tumor associated calcium signal transducer 2

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 2837

Nomenclature: tumor associated calcium signal transducer 2

Family: Tumour-associated antigens

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 323 1p32.1 TACSTD2 tumor associated calcium signal transducer 2
Mouse 1 317 6 C1 Tacstd2 tumor-associated calcium signal transducer 2
Rat 1 317 4q31 Tacstd2 tumor-associated calcium signal transducer 2
Previous and Unofficial Names Click here for help
M1S1 | EGP-1 | TROP2 | TROP-2 | GA733-1 | RS7 antigen [2] | tumor-associated calcium signal transducer 2
Database Links Click here for help
CATH/Gene3D
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia

Download all structure-activity data for this target as a CSV file go icon to follow link

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
sacituzumab govitecan Peptide Approved drug Primary target of this compound Hs Binding - - 1
[1]
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Corneal dystrophy, gelatinous drop-like; GDLD
Synonyms: Gelatinous drop-like corneal dystrophy [Orphanet: ORPHA98957]
OMIM: 204870
Orphanet: ORPHA98957
Disease:  Honey-droplet corneal dystrophy
Orphanet: ORPHA98958
General Comments
TROP2 is a an antigen that is overexpressed on the surface of tumours of the lung, breast, pancreas and other organs. Elevated TROP2 expression is associated with poor prognosis. The first anti-TROP2 ADC to be approved was Immunomedics' sacituzumab govitecan (Trodelvy®) in April 2020. AstraZeneca announced in mid-2020 that they are partnering with Daiichi Sankyo to progress Daiichi's Phase 2 anti-TROP2 ADC, DS-1062. DS-1062 is a humanised mAb conjugated to the exatecan derivative MAAA1181a (a.k.a. DXd).

References

Show »

1. Govindan SV, Qu Z, Hansen HJ, Goldenberg DM. (2013) RS7 antibodies. Patent number: US8574575. Assignee: Immunomedics, Inc.. Priority date: 01/03/2002. Publication date: 05/11/2013.

2. Stein R, Basu A, Goldenberg DM, Lloyd KO, Mattes MJ. (1994) Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb RS7. Int. J. Cancer Suppl., 8: 98-102. [PMID:8194903]

How to cite this page

Tumour-associated antigens: tumor associated calcium signal transducer 2. Last modified on 27/07/2020. Accessed on 28/11/2020. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2837.